Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

PURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin.info:eu-repo/semantics/publishedVersio

Discectomia lombar transforaminal: estudo quantitativo em cadáveres Discectomía lumbar transforaminal: estudio cuantitativo en cadáveres Transforaminal lumbar discectomy: quantitative study in cadavers

OBJETIVO: avaliar a eficácia da discectomia lombar por via transforaminal, de modo quantitativo, em estudo experimental com cadáveres. MÉTODOS: este estudo utilizou cinco cadáveres humanos frescos, submetidos à discectomia pela via de acesso póstero-lateral nos níveis L3-L4 e L4-L5, visando remover a maior quantidade de material discal possível. Uma abordagem anterior complementar, expondo os mesmos discos intervertebrais, permitiu a remoção do material discal remanescente, para posterior comparação. RESULTADOS: em L3-L4, a remoção transforaminal do disco obteve, em média, 48% do volume total, e em L4-L5, cerca de 38%. CONCLUSÃO: apesar de segura e de fácil realização, a via transforaminal não é tão eficaz quanto à via anterior na remoção do disco intervertebral.<br>OBJETIVO: evaluar la eficacia de la discectomía lumbar por vía transforaminal, de modo cuantitativo, en un estudio experimental con cadáveres. MÉTODOS: este estudio utilizó cinco cadáveres humanos frescos, sometidos à discectomía por vía de acceso posterolateral en los niveles L3-L4 y L4-L5, visando remover la mayor cantidad de material discal posible. Un abordaje anterior complementar, exponiendo los mismos discos intervertebrales, permitió la remoción del material discal remanente, para posterior comparación. RESULTADOS: en L3-L4, la remoción transforaminal del disco obtuvo en promedio 48% del volumen total y en L4-L5, cerca del 38%. CONCLUSIÓN: aunque segura y de fácil realización, la vía transforaminal no es tan eficaz como la vía anterior en la remoción del disco intervertebral.<br>OBJECTIVE: to evaluate the quantitative efficacy of transforaminal lumbar discectomy, through a cadaver study. METHODS: this study used five fresh human cadavers, that underwent L3-L4 and L4-L5 posterolateral discectomy, aiming to remove as much disc material as possible. After that, the remaining disc material was removed through an anterior approach, for further comparison. RESULTS: in L3-L4, transforaminal discectomy allowed the removal of 48% of disc volume, and in L4-L5, 38%. CONCLUSION: although safe and relatively easy to perform, the transforaminal approach does not allow complete discectomy

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

PURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin